Sale of Ozempic Knockoffs Is Supposed to End Soon. Telehealth Companies Aren’t Happy
- Dr. Bruce Moynihan
- Mar 19
- 4 min read
March (Doctors In Business Journal) - The pharmaceutical industry is in an uproar over the sale of knockoff versions of the popular diabetes and weight-loss drug, Ozempic. As pharmaceutical giants intensify efforts to curb the sale of custom-made alternatives, telehealth companies and pharmacies that rely on these products are bracing for a major hit to their revenues. The impending crackdown is creating a standoff between the established pharmaceutical giants and the rapidly growing telehealth sector. In this article, we’ll explore why the sale of Ozempic knockoffs is expected to end, why telehealth companies are unhappy about it, and what this development means for the broader health care market.
Want to read more?
Subscribe to doctorsinbusinessjournal.com to keep reading this exclusive post.
